An evaluation of fructosamine estimation in screening for gestational diabetes mellitus

Diabet Med. 1995 Aug;12(8):708-12. doi: 10.1111/j.1464-5491.1995.tb00574.x.


Although persuasive arguments against routine screening for gestational diabetes mellitus (GDM) have been made, it is widely but not universally performed as a part of antenatal care. There is no international agreement on methods or criteria used for screening (or for diagnosis), and administered glucose-load methods have significant practical difficulties in a busy antenatal clinic setting. However, recent evidence supports the concept of an increased level of importance being given to a diagnosis of GDM, with interest in the fetal and neonatal origins of adult disease being added to the short-term obstetric and fetal concern during pregnancy. A second generation fructosamine test, corrected for total protein, has been evaluated as a practical alternative to glucose screening for GDM in a busy, multi-ethnic antenatal clinic. This achieved a 79.4% sensitivity and a 77.3% specificity for a diagnosis of GDM confirmed by a glucose tolerance test using Carpenter's modified criteria. In view of the organizational simplicity of this sample/test requirement, a wider evaluation is suggested together with a re-evaluation of clinical outcome criteria rather than blood glucose levels alone.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / blood*
  • Blood Glucose / analysis
  • Diabetes, Gestational / blood
  • Diabetes, Gestational / diagnosis*
  • Diabetes, Gestational / prevention & control
  • Fasting
  • Female
  • Fructosamine
  • Glucose Tolerance Test*
  • Hexosamines / blood*
  • Humans
  • Infant, Newborn
  • Mass Screening
  • Pregnancy
  • Prenatal Care
  • Sensitivity and Specificity


  • Biomarkers
  • Blood Glucose
  • Hexosamines
  • Fructosamine